论文部分内容阅读
Hellman及其同事们在ICRF实验室进行药物筛选,发现ICRF154口服对实验肿瘤L_(1210)和肉瘤S_(180)意外有效。在临床试用中既不活泼也没毒性,认为吸收差与药物不溶解有关。
Hellman and colleagues conducted drug screening in the ICRF laboratory and found that ICRF154 was orally potent in the experimental tumor L 1210 and sarcoma S 180. In clinical trials neither live nor toxic, that poor absorption and drug insolubilization.